精确的治疗性生物标志物鉴定及其在癌症基因组计划中的应用
Precision Therapeutic Biomarker Identification with Application to the Cancer Genome Project
摘要:
癌细胞系经常被用于将药物敏感性和耐药性与基因组图谱联系起来。为了捕获癌症中的基因组复杂性,癌症基因组计划(CGP)(Garnett等人,2012)用130种药物筛选了639种人肿瘤细胞系,所述药物的范围从已知的化疗剂到实验化合物。感兴趣的问题包括:i)是否可以检测到癌症特异性治疗生物标志物,ii)是否可以识别耐药性模式以及使用替代药物规避耐药性的预测策略,iii)是否可以预测药物协同作用的生物标志物?为了解决这些问题,仍然存在以下统计挑战:i)生物标志物在细胞系之间聚类; ii)聚类可以重叠(例如,细胞系可以属于多个聚类); iii)药物应该联合建模。本文提出了一个隐含重叠聚类指标变量的多元回归模型来解决上述问题。提出了与新模型相联系的广义有限混合多元回归模型(FMMR)和一种新的期望最大化算法。对数据集的重新分析揭示了癌症之间的治疗相互关系以及用于治疗和管理癌症的现有和新型药物行为。
英文摘要:
Cancer cell lines have frequently been used to link drug sensitivity and resistance with genomic profiles. To capture genomic complexity in cancer, the Cancer Genome Project (CGP) (Garnett et al., 2012) screened 639 human tumor cell lines with 130 drugs ranging from known chemotherapeutic agents to experimental compounds. Questions of interest include: i) can cancer-specific therapeutic biomarkers be detected, ii) can drug resistance patterns be identified along with predictive strategies to circumvent resistance using alternate drugs, iii) can biomarkers of drug synergies be predicted ? To tackle these questions, following statistical challenges still exist: i)biomarkers cluster among the cell lines; ii) clusters can overlap (e.g. a cell line may belong to multiple clusters); iii) drugs should be modeled jointly. We introduce a multivariate regression model with a latent overlapping cluster indicator variable to address above issues. A generalized finite mixture of multivariate regression (FMMR) model in connection with the new model and a new EM algorithm for fitting are proposed. Re-analysis of the dataset sheds new light on the therapeutic inter-relationships between cancers as well existing and novel drug behaviors for the treatment and management of cancer.
机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。